3-Isopropyl-N,4-dimethylaniline | 66789-72-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Isopropyl-N,4-dimethylaniline
• 英文别名: N,4-dimethyl-3-propan-2-ylaniline
• CAS: 66789-72-8
• 化学式: C₁₁H₁₇N
• 分子量: 163.26
• InChiKey: KQRYCJBFMBFSBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Substituted cinnolines as inhibitors of KRAS G12C
  申请人：Araxes Pharma LLC

  公开号：US10927125B2

  公开（公告）日：2021-02-23

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  本研究提供了具有抑制 G12C 突变 KRAS 蛋白活性的化合物。这些化合物具有以下结构 (I)： 或其药学上可接受的盐、同系物、原药或立体异构体，其中 R1、R2a、R3a、R3b、R4a、R4b、G1、G2、L1、L2、m1、m2、A、B、W、X、Y、Z 和 E 如本文所定义。还提供了与制备和使用此类化合物相关的方法、包含此类化合物的药物组合物以及调节 G12C 突变 KRAS 蛋白活性以治疗疾病（如癌症）的方法。
• [EN] QUINOXALINE DIONE DERIVATIVE AS IRREVERSIBLE INHIBITOR OF KRAS G12C MUTANT PROTEIN<br/>[FR] DÉRIVÉ DE QUINOXALINE DIONE EN TANT QU'INHIBITEUR IRRÉVERSIBLE DE LA PROTÉINE MUTANTE KRAS G12C<br/>[ZH] 喹喔啉二酮衍生物作为KRAS G12C突变蛋白的不可逆抑制剂
  申请人：BEIJING TIDE PHARMACEUTICAL CO LTD

  公开号：WO2021219090A1

  公开（公告）日：2021-11-04

  一种式（I）所示的喹喔啉-2,3(1H,4H)-二酮衍生物、其制备方法以及包含所述衍生物的药物组合物。该类化合物可作为KRAS G12C突变蛋白的不可逆抑制剂，用于治疗癌症等疾病。
• SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C
  申请人：Araxes Pharma LLC

  公开号：US20200102321A1

  公开（公告）日：2020-04-02

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R 1 , R 2a , R 3a , R 3b , R 4a , R 4b , G 1 , G 2 , L 1 , L 2 , m 1 , m 2 , A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
• IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS
  申请人：1ST Biotherapeutics, Inc.

  公开号：US20200270246A1

  公开（公告）日：2020-08-27

  The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound.
• CHARGE-BEARING CYCLODEXTRIN POLYMERIC MATERIALS AND METHODS OF MAKING AND USING SAME
  申请人：CycloPure, Inc.

  公开号：US20220017645A1

  公开（公告）日：2022-01-20

  The present disclosure relates to charge-bearing polymeric materials and methods of their use for purifying fluid samples from micropollutants, such as anionic micropollutants.